Glowing dye could replace radioactive markers for breast cancer surgery
NCT ID NCT03313908
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a fluorescent dye called indocyanine green (ICG) can help surgeons locate small, non-palpable breast tumors during surgery. Ten women with early-stage breast cancer received both the dye and a standard radioactive seed, and doctors compared how well each method pinpointed the tumor. The goal is to see if ICG could replace the radioactive method, making the procedure simpler and more comfortable for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
indocyanine green (ICG)
What this could lead to
If successful, this could offer a simpler, non-radioactive way to locate small breast tumors during surgery, improving patient comfort and hospital logistics.
What could go wrong
This is a very small feasibility study with only 10 participants, so results may not apply broadly. The technique may not be as accurate as the current standard.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UH Montpellier
Montpellier, 34295, France